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ABSTRACT
ANTIDEPRESSANTS AND MELANOMA: IS THERE A LINK? Stephanie R. Douglas, Deepak Narayan.
Section of Plastic and Reconstructive Surgery, Department of Surgery, Yale University School of
Medicine, New Haven, CT.
Cutaneous melanoma is the sixth most common cancer in the United States, and its incidence
continues to rise steadily at a rate of 2-3% per year. Meanwhile nearly 11% of the general population is
treated with antidepressant medication. Laboratory studies suggest a number of theoretical links between
antidepressants and melanoma. Serotonin is a growth factor for melanocytes, and antidepressants
upregulate components of the Wnt/beta-catenin, mTOR, and MAP kinase signaling pathways, all of which
may be involved in melanoma transformation and carcinogenesis. To investigate the potential link between
antidepressants and melanoma in vivo, localized tumors were induced in a conditional mouse model of
BrafV600E-induced, Pten-deficient melanoma. Citalopram hydrobromide in 0.1% saccharin was administered
at a dose of 20 mg/kg/day orally via drinking water beginning at the time of melanoma induction. Control
animals received 0.1% saccharin. At weekly intervals, the overall tumor volume was assessed so that the
tumor growth rate could be calculated for each mouse. At day 75 following tumor induction, necropsy was
performed to assess for the presence of metastases. Antidepressant administration appeared to have no
effect on tumor volume at any of the time points measured (day 29, p=0.997; day 36, p=0.761; day 44,
p=0.612; day 50, p=0.682; day 57, p=0.797; day 66, p=0.691; day 75, p=0.736), or on metastasis.
Secondly, the charts of 1271 patients treated for melanoma at Yale Cancer Center between 1997 and 2013
were reviewed, taking particular note of medication history. A health history questionnaire eliciting
information about melanoma risk factors as well as medication histories was administered to patients seen
at an outpatient surgery clinic at Yale-New Haven Hospital who had no history of melanoma. Age, sex, and
group (cases or controls) were entered into a binary logistic regression model to calculate an adjusted odds
ratio for antidepressant exposure as a function of group. Additionally, age, sex, and tumor stage were
entered into a second model for the odds of antidepressant exposure as a function of tumor stage.
Melanoma patients were less likely to have a history of antidepressant use relative to controls (OR 0.567,
95% CI 0.331-0.972, p=0.039). There was no association between antidepressants and melanoma stage at
diagnosis. Further study is needed in order to clarify the nature of the association between antidepressants
and melanoma risk.
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INTRODUCTION
Cutaneous melanoma is the sixth most common cancer in the United States and
the most common fatal malignancy that afflicts young adults. The incidence of melanoma
continues to rise steadily at a rate of 2-3% per year. (1) Melanoma risk is affected by both
genetic and environmental factors, the most salient of which are skin color, sun exposure,
immunocompromised status, and a personal or family history of melanoma. In addition to
these known risk factors, however, certain hormones and medications (e.g. oral
contraceptives, voriconazole) are postulated to play a role. (2, 3)
Antidepressants are one category of medications commonly used in the general
population, including patients with melanoma or those at high risk for the disease. Nearly
10% of the general population is estimated to suffer from a mood disorder, and
depression is the leading cause of disability in the United States for people between the
ages of 15 and 44. (4, 5) Many of these patients are treated with antidepressant
medication. Furthermore, use of antidepressant medication is not limited to the treatment
of depression; these drugs are used to treat anxiety, chronic pain, and a variety of other
conditions as well. According to National Health and Nutrition Examination surveys
conducted in the years 2005-2008, antidepressants are used by nearly 11% of people over
the age of 12. In some subsets of the population, the rate of antidepressant use may reach
nearly 23%. (6)
Even with an extensive literature on antidepressants and overall cancer risk, the
data are inconclusive. Adding to the uncertainty is the fact that few studies have directly
investigated the effect of antidepressant exposure on melanoma incidence and prognosis.
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Given the large number of people taking antidepressant medication and the potentially
lethal nature of melanoma, any link between the two would be cause for grave concern.
Serotonin and melanocytes
Though there are many different classes of antidepressants, all are believed to
affect serotonin pathways (Table 1, Appendix I). The most commonly prescribed
antidepressants fall into the selective serotonin reuptake inhibitor (SSRI) or serotoninnorepinephrine reuptake inhibitor (SNRI) classes. These drugs increase the levels of
neurotransmitters in the neural synapse by inhibiting the reuptake of serotonin (in the
case of SSRIs) or both serotonin and norepinephrine (in the case of SNRIs) by the
presynaptic neuron. Because of their favorable side-effect profile and relative safety in
overdose, SSRIs are often first-line agents for the treatment of depression. Tricyclic
antidepressants similarly inhibit reuptake of serotonin and norepinephrine, and
monoamine oxidase inhibitors, or MAOIs, irreversibly inhibit the enzyme responsible for
the breakdown of serotonin, norepinephrine, and dopamine. Even the atypical
antidepressants are thought to have some effect on serotonin systems, though the
importance of this in the efficacy of these drugs for treating depression is unknown.
Serotonin plays an important role in cutaneous physiology, and the skin is a site
of both production and action of serotonin. Serotonin is synthesized from tryptophan in a
reaction catalyzed by tryptophan hydroxylase, an enzyme that has been detected in
biopsies of normal skin as well as normal melanocytes in culture and melanoma cell
lines. Immunohistochemical studies have identified the presence of serotonin in
epidermal and adnexal structures as well as within the dermis. (7, 8) The skin is also able
to convert serotonin to melatonin, and functional receptors for serotonin and melatonin
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are expressed in keratinocytes and fibroblasts, as well as melanocytes. (9) Melatonin
activates pathways protective against oxidative stress, while serotonin has vasoactive and
immunomodulating effects. (8)
Serotonin serves as a growth factor for many cell types, including hepatocytes,
basal cells, fibroblasts, and smooth muscle cells. With regard to melanocytes, serotonin
has been shown to either stimulate or inhibit cell proliferation depending on culture
conditions. (7) Interestingly, the serum concentration of serotonin is elevated following
exposure to ultraviolet light, which itself is the most important environmental risk factor
for cutaneous malignancies. (10)
The precise mechanism of antidepressants’ effects on mood has not been
completely elucidated. However, antidepressants are believed to stimulate neurogenesis
in regions of the brain such as the hippocampus, and this may play a role in the
antidepressant effects of these compounds. (11) As derivatives of the neural crest,
melanocytes may be similarly affected by antidepressant drugs.
Immunomodulatory effects of antidepressants
Immunosuppression is associated with a heightened risk for melanoma as well as
a poorer prognosis. (12-14) Melanoma occurs at an increased rate in solid organ
transplant recipients (RR 2.1-3.6), patients with lymphoma (RR 1.75-6.17) and patients
with HIV (RR 2.6 [95% CI 1.9-3.6]). (15)
SSRIs have been shown to cause impairment of immune function. Herpes simplex
virus reactivation has been observed in a number of patients taking fluoxetine, which is
thought to be related to problems with cell-mediated immunity. (16) Furthermore,
antidepressants can trigger a lupus-like illness in some patients. (17) Fluoxetine and

	
  

4

amitriptyline have been shown to inhibit normal lymphocyte proliferation in vivo in a
rodent model. (18) Due to the important role of the immune system in clearance of
melanoma cells, drugs that compromise immune function could allow melanoma tumors
to grow unchecked.
Wnt/beta-catenin signaling
Antidepressants are known to interact with pathways that are thought to be
involved in the pathogenesis of melanoma. The Wnt signaling pathway is involved in
regulating cell proliferation and differentiation, and Wnt upregulation leads to
carcinogenesis via activation of the β-catenin pathway. Increased Wnt2 is known to lead
to carcinogenesis, and constitutive action of the Wnt/β-catenin pathway is commonly
seen in melanoma. (19, 20)
At the same time, depressed subjects show decreased Wnt signaling in the
prefrontal cortex, and this abnormal pattern is reversed with antidepressant treatment.
(21) Antidepressants cause increased expression and function of components of the WntFz-GSK3 pathway, and hippocampal overexpression of Wnt2 or downregulation of
GSK3 induces antidepressant-like effects. (21, 22) Given the ability of antidepressants to
influence Wnt signaling in cortical and limbic regions of the brain, these drugs may also
act on melanocytes, which are cells of neural crest origin.
mTOR activity
Mammalian target of rapamycin (mTOR) is a protein kinase responsible for
regulating VEGF production and cell growth in response to signals indicating growth
factor stimulation and nutrient availability. mTOR is activated in the majority of
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melanomas and functions as a growth promoter. Immunostaining for phosphoribosomal
protein S5, an indicator of mTOR activity, increases moving from benign nevus to
melanoma in situ to invasive melanoma. (23) Inhibitors of mTOR have anti-mitotic and
anti-angiogenic effects in melanoma and other cancers, and these qualities are being put
to therapeutic use in a new class of drugs being developed for the treatment of melanoma.
(24)
Meanwhile, depressed subjects show dysregulation of mTOR signaling, and there
is some evidence to suggest that mTOR activation is required for antidepressant effects.
(25) Ketamine, a fast-acting antidepressant, rapidly activates mTOR and increases
synaptogenesis in the prefrontal cortex. (21, 26) Certain other antidepressants, including
escitalopram, paroxetine, and tranylcypromine, activate mTOR as well. (27) Were this
type of mTOR activation to occur within the cutaneous milieu, antidepressants could
perhaps influence the incidence or clinical behavior of melanoma.
MAP kinase signaling
The BRAF gene encodes a protein involved in regulating MAP kinase and ERK
signaling, which is involved in cell division and differentiation. BRAF activating
mutations are present in as many as 80% of nevi and 50% of melanomas, leading to
activation of the MAP kinase pathway and increased production of VEGF and matrix
metalloproteinases. (28, 29) The MAP kinase pathway is thought to be an important
pathway in melanoma transformation. (30) Likewise, the pathway seems to be involved
in depression and the response to antidepressant treatment, with acute blockade of MAP
kinase signaling leading to a depressive phenotype in behavioral models of depression.
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(31) In addition, disruption of the MAP kinase signaling cascade leads to inhibition of
antidepressant effects. (21, 31)
Antidepressants and cancer risk
Previous studies suggest a broad theoretical basis for an association between
antidepressant medication and cancer risk. Many antidepressants are structurally similar
to antihistamines and tamoxifen, which have known tumor-promoting ability. (32) SSRIs
bind to growth-regulating intracellular histamine receptors associated with antiestrogen
binding sites affecting the cytochrome P450 enzyme system, which is involved in the
metabolism of carcinogens. (33, 34)
Preclinical studies have shown that serotonin may mediate cell proliferation in
colonic tumor cells, and inhibition of serotonin uptake results in suppression of cell
proliferation. (35) Some authors have described a biphasic response curve for fluoxetine
and amitriptyline with low concentrations stimulating pancreatic cancer, colorectal
cancer, and glioma growth and high concentrations inhibiting the growth of tumors. (36)
Clinical studies of antidepressants and cancer risk have yielded mixed results.
(37) Most studies have shown no statistically significant difference in cancer risk
following use of antidepressants from multiple drug classes. (38-42) However, a small
number of studies have demonstrated an increased risk of epithelial ovarian cancer in
association with tricyclic antidepressants. (43, 44) Still others have suggested that the
effect of antidepressants with regard to breast, esophageal, and gastric cancer risk is
dependent on the timing and duration of exposure. (45-47)
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Antidepressants and melanoma: in vitro and animal literature
A small number of animal studies have directly studied the effect of
antidepressants on melanoma growth and metastasis in animal models. In a rodent model
of in vivo melanoma growth, tumors showed a two-to-three-fold greater rate of growth in
mice receiving daily intraperitoneal injections of fluoxetine or amitriptyline at clinically
relevant doses as compared to a control group of animals not injected with an
antidepressant. (18)
Another study examined the effects of pretreatment with desipramine or
fluoxetine on primary tumor growth, metastasis formation, and mortality rate in mice
subsequently inoculated with B16F10 melanoma cells. (48) In young males, desipramine
promoted development of metastases and increased the mortality rate in spite of
inhibiting growth of the primary tumor. This prometastatic effect was associated with an
increase in plasma levels of VEG-F and MMP-9. In aged animals, both antidepressants
increased primary tumor growth and had a moderate stimulatory effect on metastasis
formation.
In contrast, a similar study examined the effect of intraperitoneally injected
fluoxetine, desipramine, and mirtazapine in the B16F10 melanoma model and found that
fluoxetine had a dramatic inhibitory effect on melanoma tumor growth. (49) In this study,
desipramine tended to decrease tumor growth as well, while mirtazapine had no effect.
Previous studies by this group on the effect of fluoxetine on growth of S19 melanoma in
female DBA/2 mice showed that fluoxetine had an inhibitory effect when low doses of
cells were inoculated subcutaneously, but that effect disappeared when higher number of
cells were introduced. (50)
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While antidepressants upregulate activity in a number of pathways associated

with the pathogenesis of melanoma, they may also influence other pathways in ways that
serve to inhibit tumor growth. For example, one of the reasons melanoma is poorly
responsive to chemotherapy and radiation is that tumor cells constitutively express Akt,
protecting them against apoptosis. Sertraline is a potent inhibitor of the phosphorylation
of Akt, and in vitro studies have demonstrated that sertraline can cause induction of
endoplasmic reticulum and death of melanoma cells. (51) When sertraline was
administered to mice with A375 melanoma xenografts, the drug appeared to inhibit tumor
growth in vivo, perhaps due to downregulation of Akt, though the results did not achieve
statistical significance.
Tricyclic antidepressants have likewise shown inhibitory effects on melanoma
growth under certain conditions. Two cell lines and eight primary cell cultures from
melanoma metastases were exposed to nortriptyline, clomipramine, and amitriptyline. All
three drugs inhibited tumor cell growth, though nortriptyline was more active than the
others. (52)
Interestingly, fluoxetine has been shown to act as an antioxidant in the B16F10
mouse model of melanoma, with fluoxetine preventing against melanoma-induced
oxidative changes in the mouse spleen. (53) The implications of this in human disease are
unknown.
Antidepressants and melanoma risk in humans
To date, few studies have investigated the relationship between antidepressants
and melanoma in humans. Unpublished data from a cohort of patients with melanoma
treated in the Yale Melanoma Unit demonstrated a higher incidence of multiple
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melanomas in patients being treated with an SSRI or SNRI, with multiple primary lesions
in 15% of such patients as compared to the overall rate of 6.4% identified in a prior
study.
With conflicting data in the basic science literature and a paucity of data in human
subjects, further study of the possible link between antidepressants and melanoma is
clearly warranted. Antidepressants are widely prescribed to a large segment of the
population for a variety of medical conditions. Thus, if antidepressants were to influence
the incidence or progression of melanoma, the implications would be far-reaching,
affecting treatment decisions not only for melanoma patients with coexisting depression
but possibly also the larger body of patients with conditions for which antidepressants are
often prescribed.
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PURPOSE, HYPOTHESES, AND SPECIFIC AIMS
Despite the many theoretical links between serotonin and the development and
progression of melanoma, the effect of antidepressants on the incidence and outcome of
melanoma is unknown. By investigating the effect of citalopram on tumor latency, tumor
number, and tumor growth trajectory in mice that are genetically programmed to develop
melanoma, this study sheds light on an important question that remains poorly
understood. The epidemiological component of the study serves as a first step to
understanding the effect of antidepressants on melanoma risk in humans. Due to the
growth-stimulatory effects of serotonin on melanocytes, the immunomodulatory effects
of antidepressants, and the ability of antidepressants to interact with signaling networks
(e.g. Wnt, mTOR, MAP kinase) in a way that may be favorable to melanoma
tumorigenesis, we hypothesized that antidepressants may increase the risk for developing
melanoma or may otherwise alter tumor growth characteristics.
Aim 1: To investigate the effect of antidepressants on tumor growth rate in vivo using a
mouse model of melanoma.
Antidepressants are known to affect a number of pathways thought to be involved
in melanoma pathogenesis, and serotonin is a growth factor for melanocytes. Citalopram
is a highly serotonergic antidepressant of the SSRI class and is widely used to treat
depression and anxiety due to its favorable side-effect profile. The Braf/Pten melanoma
model described below features tumors with genetic lesions that are common in human
melanoma and offers control over the timing and location of tumor initiation. This study
is the first to examine the effect of antidepressant medication on the growth
characteristics of melanoma tumors arising in vivo. We hypothesized that citalopram
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would enhance melanoma tumor growth, leading to an increased tumor growth rate in a
mouse model of melanoma.
Aim 2: To compare the prevalence of antidepressant use among patients treated for
melanoma at Yale Cancer Center from 1997-2013 with that of control patients seen at an
outpatient surgery clinic at Yale with no history of melanoma.
Preliminary review of data from a subset of patients treated at the Yale Melanoma
Unit reveals a higher-than-average rate of antidepressant use as well as an increased
number of patients with multiple primary melanomas among those taking
antidepressants. We hypothesized that the melanoma patient population would exhibit a
higher rate of antidepressant exposure (at or prior to the time of melanoma diagnosis)
relative to an age- and sex-matched control population seen at an outpatient surgery clinic
at Yale with no history of melanoma.
Aim 3: To compare the rate of antidepressant exposure among melanoma patients with
early melanoma tumors and those with more advanced disease who were treated at Yale
Cancer Center from 1997-2013.
Prior studies in animal models of melanoma have shown that antidepressants
potentially affect not only the rate of growth of the primary tumor but also the propensity
of the tumor to metastasize. We hypothesized that melanoma progression would be
facilitated by the presence of antidepressants in patients taking these medications, such
that melanoma patients presenting with late-stage disease would be more likely to have a
history of antidepressant exposure.
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METHODS
Aim 1: Mouse model
MELANOMA MODEL: The experiments in Aim 1 utilized the conditional mouse model of
BrafV600E-induced, Pten-deficient melanoma described in Dankort et al. 2009 to
investigate the effect of citalopram on melanoma growth parameters in vivo. (54) BRAF
activating mutations are present in 80% of nevi and 50% of melanomas, forming the
basis for this model. (54, 55) The combination of mutated BRAF and silencing of PTEN
is found in 20% of melanomas. (55) The Braf/Pten melanoma model has been
successfully used by investigators at Yale to study pharmacologic agents that influence
signaling pathways implicated in the pathogenesis of melanoma. Because this model
recapitulates the genetic lesions commonly found in human melanoma, the effect of
pharmacologic agents on the development and progression of melanoma in these animals
is thought to parallel the processes that occur in human patients with melanoma. BrafV600E
cell lines derived from Braf/Pten mice have been shown to respond to inhibition of
mTorc1 and MEK1/2 using rapamycin and PD325901, respectively, suggesting that the
biological behavior of tumors in these animals is similar to that of melanoma tumors in
humans. (54)
The Braf/Pten melanoma model allows localized tumors to be induced by topical
application of 4-hydroxytamoxifen (4-HT), with 100% penetrance within 10 weeks
(Figure 1). (55) In these animals, the Cre-recombinase::estrogen receptor (CreER) fusion
protein is constitutively expressed in melanocytes by Tyr transgenic promoter elements.
Exposure to 4-HT causes CreER to be released from Hsp90 and translocate to the
nucleus, where it results in the removal of DNA sequences between loxP sites and
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consequent activation or inactivation of the gene of interest (here, BRAF). (55) In prior
rodent studies investigating the possible association between antidepressants and
melanoma, mice received subcutaneous or intravenous injections of B16F10 mouse
melanoma cells that had been grown in culture, or melanoma xenografts. (18, 48-51, 53)
The Braf/Pten model more closely replicates the biology of melanoma in humans, and the
clinical behavior of such tumors likely has greater relevance to the human population.

Figure 1: Braf/Pten mouse model of melanoma
Schematic showing induction of melanoma with 4-HT. The Cre-recombinase::estrogen
receptor (CreER) fusion protein is constitutively expressed in melanocytes by Tyr
transgenic promoter elements, Exposure to 4-HT causes CreER to be released from
Hsp90 and translocate to the nucleus, where it results in removal of DNA sequences
between loxP sites and subsequent activation or inactivation of the gene of interest.
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Animals were housed in groups of 1-3 animals per cage in a temperaturecontrolled environment under a 12-hour light-dark cycle. Standard food and drinking
water solutions (described below) were freely available. Animal experiments were
performed in accordance with a protocol approved by the Institutional Animal Care and
Use Committee at Yale University (IACUC protocol #2011-11211).
TUMOR

INDUCTION:

One major advantage of the Braf/Pten model of melanoma is that

tumor induction with 4-HT offers control over the timing and location of melanoma
initiation. Melanoma was induced on the back skin of the animals by treating adult mice
with topical administration of 1-2 µl of 1.9 mg/ml (5 mM) 4-HT at 3 weeks of age.
DRUG

ADMINISTRATION:

Citalopram hydrobromide was chosen for these experiments

because its high binding affinity for the serotonin transporter makes it highly selective for
serotonin. In view of serotonin’s role as a growth factor for melanocytes, a highly
serotonergic antidepressant was felt to be desirable for these experiments. Citalopram has
been used extensively in rodent studies and is commonly prescribed for the treatment of
depression and anxiety due to its favorable side-effect profile.
Antidepressant administration began at the time of tumor induction with 4-HT
and continued until the study endpoint (outlined below) was reached (Figure 2).
Citalopram hydrobromide (Sigma-Aldrich, St. Louis, MO) was administered orally via
drinking water at a dose of 20 mg/kg/day to the animals in the experimental group. The
drinking water solution contained 0.1% saccharin to mask the taste of the drug. Control
animals received 0.1% saccharin. Animals were denied access to other sources of
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drinking water. There were two animals in the control group receiving saccharin solution,
while four animals received citalopram/saccharin solution.

Figure 2: In vivo study design
Tumor is induced by topical application of 4-hydroxytamoxifen when the mouse is 3
weeks of age. Antidepressant/placebo administration begins at the time of tumor
induction. Tumors reach 1 mm3 in size by 4 weeks post-tumor induction. Study endpoint
is reached when tumor measures 2 cm3.
4-HT 4-hydroxytamoxifen

Saccharin solution (0.1%) was prepared by adding 200 mg saccharin (SigmaAldrich, St. Louis, MO) to 200 ml near-boiling water and stirring until dissolved. For the
citalopram solution, 22 mg citalopram hydrobromide was added to the warm saccharin
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solution to achieve a concentration of 0.11 mg/ml, and the solution was gently swirled
until no visible solid remained. Solutions were allowed to cool to room temperature
before being placed in the animals’ cages. Fresh drinking water solutions were prepared
every five days. The concentration of drug in solution was calculated to achieve a dose of
20 mg/kg/day assuming an average water intake of 6.7 ml/day per mouse and a weight of
30 g per mouse.
TUMOR ASSESSMENT: At weekly intervals, the overall tumor volume was assessed so that
the tumor growth rate could be calculated for each mouse according to the following
procedure: Each week, the maximal and minimal dimensions of each tumor were
measured, along with tumor thickness. Tumor volumes (V) were calculated using the
formula V=4/3πLWD, where L was the longer dimension of the tumor, W the smaller
dimension, and D the depth. Aggregate tumor volumes were calculated for each animal
as the sum of the volume of the individual tumors, and this was plotted against time in
days since the first melanoma lesion became visible.
STUDY

ENDPOINT AND EVALUATION OF METASTASES:

In accordance with the approved

IACUC protocol, animals were euthanized by cervical dislocation when the largest
melanoma tumor reached 2 cm3. Necropsy was performed on control and experimental
animals immediately following euthanasia. Lymph nodes (bilateral axillary and inguinal),
lungs, liver, spleen, and brain were removed and assessed for visible metastases. For
larger structures such as the lungs, liver, and brain, organs were serially sectioned to
allow for more thorough evaluation. Ears, paws, and tail were examined for the presence
of cutaneous metastases as well. Owing to the difficulty of assessing the precise size of
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the metastatic deposits, metastases were categorized as either “present” or “absent.”
STATISTICAL

ANALYSES:

Tumor latency, tumor number, and tumor growth rate were

expressed as a mean value ± standard deviation (SD). T-tests were performed to evaluate
differences between experimental and control groups, and p-values of <0.05 were
considered to be statistically significant.
Aim 2: Case-control study
MELANOMA

PATIENTS:

Patients were selected from among those presenting to Yale

Cancer Center between the years of 1997 and 2013 with a diagnosis of melanoma. Yale
Cancer Center is the largest melanoma treatment center in Connecticut and has a
catchment area covering much of New England. Patients were drawn from the case logs
of the two surgeons responsible for the vast majority of surgical therapy for patients with
cutaneous melanoma presenting to Yale Cancer Center. Patients who did not receive
surgical treatment of melanoma at Yale-New Haven Hospital (e.g. those referred to the
medical oncologists for participation in a clinical trial) were excluded from the study.
CONTROL SUBJECTS: Potential control subjects were identified from among patients and
accompanying family members or friends presenting to two outpatient surgery clinics
(orthopedic surgery and plastic surgery) at Yale University for reasons other than
melanoma. Exclusion criteria included a personal history of prior melanoma and black
race, due to the racial composition of the population of melanoma patients.
DATA

COLLECTION:

Charts of melanoma patients were reviewed for demographic

variables; cancer risk factors, including family history; medical and surgical history,
including medication history; and details of the primary tumor (location and number of
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primary tumors, Breslow depth, Clark level, tumor stage, histologic subtype, presence of
BRAF mutations), treatment history, and disease course. When available, details of a
patient’s antidepressant exposure were noted, including the particular medication used,
the reason the antidepressant was prescribed, and the dose, timing, and duration of
treatment. Patients whose charts did not contain a medication list were excluded from the
study. Sun exposure data were not readily available in the patients’ charts.
Data collection began with the charts of all patients treated by the primary thesis
advisor (DN). Data collection then proceeded alphabetically through the remaining charts
due to the large number of patients treated by the senior surgeon during the selected time
frame. A subset of charts was examined by a second reviewer to confirm the accuracy
and completeness of the data being collected.
The chart review was approved by the Human Investigations Committee at Yale
University and conducted in accordance with protocol # 0609001869. Charts were
reviewed in hospital-designated reading rooms. No identifying information was collected.
Data were stored in a password-protected file on a computer protected by universitystandard whole disk encryption accessible only by those conducting the chart review.
To obtain data from control subjects, an online health history questionnaire was
administered in the waiting room of surgical subspecialty outpatient clinics (plastic
surgery and orthopedic surgery) to patients and their accompanying family members or
friends between August 2013 and January 2014. Questionnaires were administered using
a laptop computer or an iPad belonging to a member of the research team. Participants
were invited to take part in a research study “designed to learn more about the risk factors
for melanoma.” Participants were not given any indication that the study was specifically
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aimed at investigating antidepressant exposure as a cancer risk factor.
The full content of the health history questionnaire can be found in Appendix II.
Briefly, the questionnaire included demographic information (age, city/state of residence,
reason for presenting to clinic); melanoma risk factors (hair and eye color, skin tone, sun
reaction); social history (tobacco and alcohol use, occupation); past medical history,
including malignancy history; past surgical history; family history of malignancy. The
questionnaire also directly queried subjects about current or past use of NSAIDs,
anticoagulants, and antidepressants.
STATISTICAL

ANALYSES:

Statistical analyses were performed using SPSS statistical

software (IBM, Armonk, NY). Variables were first bivariately tested for differences
between cases and controls using the chi-square test. Variables were then entered in a
model of binary logistic regression, with antidepressants as the dependent variable and
group as the first covariate. Age and sex were included in the second block of covariates
to control for the effect of these variables. Results were expressed as an odds ratio with
95% confidence interval, with p values <0.05 considered statistically significant.
Aim 3: Melanoma cohort by stage
DATA COLLECTION: Data collected from the melanoma patients according to the methods
described under Aim 2 above was used to determine and compare the rate of
antidepressant exposure among patients with early and late disease. For the first set of
analyses, patients were first grouped into stage 0, I, II, III, and IV. Because the detailed
pathology reports revealing the presence or absence of ulceration and number of mitoses
were not always present in the patients’ charts, the A, B, and C subclassification was not
specified. Data were then reanalyzed with patients divided into in situ, early-, and late-
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stage melanomas. Early melanomas were defined as stage I, while late melanomas were
defined as stage II, III, or IV.
STATISTICAL

ANALYSES:

Individual variables were initially tested using the chi-square

test to determine any differences between groups. Binary logistic regression was then
performed with antidepressant exposure as the dependent variable and age and sex as
covariates. Tumor stage was included as a covariate in Block 2. Results were expressed
as an odds ratio and 95% confidence interval, with p-values <0.05 considered statistically
significant. SPSS software was used for these analyses.
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RESULTS
Aim 1: Mouse model
Weekly tumor measurements began on post-induction day 29. Aggregate tumor
volumes for control and experimental animals are shown in Table 2. The volumes listed
represent the sum of the volumes of the individual tumors for each animal.

Table 2: Aggregate tumor volumes for control and experimental animals
Aggregate Tumor Volume (mm3)B,C
Days PostInductionA

A

Control

Experimental

29

C1
129.35

C2
82.65

E1
24.35

E2
2.07

E3
99.11

E4
297.22

36

252.90

163.48

160.56

5.98

105.86

428.96

44

352.86

217.07

118.79

21.24

105.96

579.00

50

444.82

246.33

129.19

22.41

174.67

727.38

57

550.41

265.75

328.44

42.16

389.79

1183.04

66

1102.32

480.49

361.11

28.73

433.29

1551.65

75

2200.49

477.64

545.13

41.96

706.01

2399.25

Refers to the number of days after melanoma was induced with 4-HT.

B

Tumor volumes (V) calculated using the formula V=4/3πLWD, where L was the longer dimension of the
tumor, W the smaller dimension, and D the depth.
C

Aggregate tumor volume calculated as the sum of the volume of individual tumors.

Aggregate tumor volume was plotted against days following tumor induction for
each animal to yield the chart shown in Figure 3 below. Animals C1 and E4 showed
exponential tumor growth, whereas animals C2, E1, and E3 showed linear tumor growth
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over the time period in which data were collected. Animal E2 demonstrated a very slow
rate of tumor growth for the duration of the experiment.

3000	
  

Agregate	
  Tumor	
  Volume	
  (mm3)	
  

2500	
  

2000	
  

C1	
  
C2	
  
1500	
  

E1	
  
E2	
  
E3	
  

1000	
  

E4	
  
500	
  

0	
  
29	
  

36	
  

44	
  

50	
  

57	
  

66	
  

75	
  

Days	
  Post-‐Induc:on	
  

Figure 3: Melanoma growth trajectory in control and experimental animals
C1, C2: control animals
E1, E2, E3, E4: experimental animals

No difference was detected between control and antidepressant-exposed animals
at any of the time points measured (p=0.612 to p=0.997; Table 3).
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Table 3: Student’s t-test for tumor growth
Mean±SD
Control (n=2)
Experimental (n=4)

p-value

Day 29

106.00±33.02

105.67±134.26

0.997

Day 36

208.19±63.23

175.34±180.79

0.761

Day 44

284.97±96.02

206.25±252.24

0.612

Day 50

345.58±140.35

263.41±315.82

0.682

Day 57

408.08±201.29

485.86±488.86

0.797

Day 66

791.40±439.71

593.70±662.49

0.691

Day 75

1324.07±1239.45

923.09±1023.95

0.736
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Figure 4: Mean tumor volumes for control and experimental animals
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By day 75, one animal from each group had reached the study endpoint of a tumor
volume of 2 cm3, and all animals were euthanized. At the time of necropsy, four animals
had evidence of cutaneous metastases at one or more location (ears—4, tail—3, paws—
1). Four animals had axillary lymph nodes that were grossly positive for melanoma
(ipsilateral—3; contralateral—1). Lung metastases were present in one animal, and
another animal had a single focus of metastasis in the brain. No animals showed evidence
of grossly visible liver metastases. Cutaneous and nodal metastases were present in
control and experimental animals, whereas only animals treated with antidepressants
displayed evidence of visceral metastases (Table 4).

Table 4: Patterns of metastases in control and experimental animals
Location
Ears

Control
C1
X

Experimental

C2

E1

Tail

E2
X

E3
X

E4
X

X

X

X

3

X

1

Paws
Contralateral
LN
Ipsilateral LN

X
X

X

X
X

Liver

LN, lymph node

4

1

Lungs

Brain

Total (#
animals)

3
1
0

X

1
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Aim 2: Case-control study
The charts of 1412 melanoma patients were reviewed for this study. 141 patients
were excluded because key information (medication list, date of melanoma diagnosis)
could not be found in the patient’s chart. Thus, data from 1271 melanoma patients were
included in the analyses.
Ninety-eight control subjects agreed to participate in the study. Three subjects
were excluded because they did not complete the health history questionnaire in its
entirety or failed to provide data necessary for the analysis (e.g. age, gender,
antidepressant history, melanoma history). Eight subjects were excluded due to black
race so that the control population would more closely approximate the melanoma
population. In total, 87 control subjects were included in the analysis.
Mean age was 59.4 ± 16.6 years for the melanoma patients and 48.8 ± 16.4 years
for controls (Table 5). Of the melanoma patients, 635/1271 (50.0%) were female. Among
controls, 57/87 (65.5%) were female.

Table 5: Subject Characteristics
Variable
Age (mean ± SD)
Sex (% female)

Cases (n=1271)

Controls (n=87)

p-value

59.4 ± 16.6

48.8 ± 16.4

<0.001

50.0

65.5

0.005

For both cases and controls, females were more likely to have been exposed to
antidepressant medication (OR 2.148 [95% CI 1.564-2.950]; p<0.001). There was no
significant effect of age on antidepressant exposure (OR 1.007 [95% CI 0.998-1.017];
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p=0.117). Among melanoma patients, 182/1271 (14.3%) had a history of antidepressant
use, compared to 20/87 (23.0%) controls (Table 6).

Table 6: Data for group and history of antidepressant use
Melanoma
Patients

Controls

Total

History of antidepressant use

182

20

202

No history of antidepressant use

1089

67

1156

Total

1271

87

1358

Antidepressant Exposure

The logistical model with age and sex as covariates demonstrated that melanoma
patients were less likely to have been exposed to antidepressant use prior to or at the time
of melanoma diagnosis than were controls (OR 0.567 [95% CI 0.331-0.972]; p=0.039;
Table 7).

Table 7: Logistic regression analysis of antidepressant exposure among melanoma
patients and controls

Predictor

β

SE β

Wald's
χ2

Constant

-2.165

0.381

32.214

1

<0.001

0.115

Age

0.009

0.005

3.406

1

0.065

1.009

Gender
(0=males,
1=females)

0.749

0.162

21.321

1

<0.001

2.116

Group
(0=controls,
1=cases)

-0.567

0.275

4.265

1

0.039

0.567

eβ

df

p

(odds ratio)
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ANALYSIS

WITH SEPARATE MODELS FOR MALES AND FEMALES:

When the data were

reanalyzed using separate models for males and females, age remained insignificant
(males: OR 1.009 [95% CI 0.993-1.025]; p=0.283; females: OR 1.007 [95% CI 0.9951.018]; p=0.247). Among males, no association was seen between group (cases vs.
controls) and antidepressant use (OR 0.658 [95% CI 0.219-1.982]; p=0.457). For
females, an association between group and antidepressant use approached statistical
significance, with melanoma patients less likely than controls to have a history of
antidepressant exposure (OR 0.540 [95% CI 0.290-1.005]; p=0.052).

Aim 3: Melanoma cohort by stage
Of the 1271 melanoma patients included in the analysis for Aim 2 (above), 1257
patients had staging information available. The characteristics of the cohort are shown in
Table 8 (below).
Mean age of the subjects was 60.9 ± 15.6 years for stage 0 disease, 58.0 ± 16.3 for
stage I, 64.5 ± 17.7 for stage II, 56.4 ± 17.1 for stage III, and 55.3 ± 17.7 for stage IV. Of
subjects who presented with stage 0 disease, 176/313 (56.2%) were female. 348/675
(51.6%) of stage I subjects were female, as were 61/177 (34.5%) of stage II subjects,
35/72 (48.6%) of stage III subjects, and 9/20 (45.0%) of stage IV subjects (Table 9).
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Table 8: Characteristics of the melanoma cohort (Aim 3).
Variable

Stage 0

Stage I

Stage II

Stage III

Stage IV

p-value

Age (mean ±
SD)

60.9 ±
15.6

58.0 ±
16.3

64.5 ±
17.7

56.4 ±
17.1

55.3 ±
17.7

0.008

56.2

51.6

34.5

48.6

45.0

<0.001

Sex (% female)

Table 9: Data for tumor stage at diagnosis.
Stage
Sex

0

I

II

III

IV

Total

Male

137

327

116

37

11

628

Female

176

348

61

35

9

629

Total

313

675

177

72

20

1257

In the entire melanoma cohort, females were more likely to have been exposed to
antidepressant medication (OR 2.067 [95% CI 1.485-2.877]; p<0.001). There was no
significant effect of age on likelihood of antidepressant exposure (OR 1.008 [95% CI
0.998-1.017]; p=0.127).
The logistical model with age and sex as covariates demonstrated that there was
no effect of tumor stage on the likelihood of antidepressant exposure at the time of
melanoma diagnosis (OR 0.945 [95% CI 0.784-1.139]; p=0.553; Table 10).
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Table 10: Logistic regression analysis of antidepressant exposure among melanoma
patients by tumor stage

Predictor

β

SE β

Wald's
χ2

Constant

-2.568

0.359

51.060

1

<0.001

0.077

Age

0.008

0.005

2.287

1

0.130

1.008

Gender
(0=males,
1=females)

0.717

0.169

17.904

1

<0.001

2.048

Tumor stage
(0=MIS,
1=stage I,
2=stage II,
3=stage III,
4=stage IV)

-0.57

0.095

0.353

1

0.553

0.945

eβ

df

p

(odds ratio)
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Figure 5: Percentage of melanoma patients with history of antidepressant use at time of
melanoma diagnosis.
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OF EARLY VERSUS LATE AND IN SITU VERSUS INVASIVE LESIONS:

When the

melanoma cohort was divided into patients with melanoma in situ, early (stage I), or late
(stage II-IV) disease, logistic regression demonstrated no effect of tumor stage on
likelihood of antidepressant use before or at the time of melanoma diagnosis (OR 0.921
[95% CI 0.728-1.165]; p=0.492). Similarly, no differences in likelihood of antidepressant
use were found when classifying patients as having in situ (stage 0) or invasive (stage Istage IV) disease (OR 0.976 [95% CI 0.680-1.402]; p=0.895).
ANALYSIS USING SEPARATE MODELS FOR MALES AND FEMALES: When males and females
were analyzed separately, there was no association between age and antidepressant use
among males (OR 1.013 [95% CI 0.996-1.031]; p=0.130) or females (OR 1.005 [95% CI
0.993-1.017]; p=0.432). Males had a mean age of 62.07±15.87. Females had a mean age
of 56.74±16.98. Melanoma stage at diagnosis was not a significant predictor of prior or
concurrent antidepressant use for either males (OR 1.125 [95% CI 0.847-1.493];
p=0.417) or females (OR 0.835 [95% CI 0.650-1.073]; p=0.159).
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DISCUSSION
To our knowledge, this is the first study to investigate the effect of an
antidepressant on melanoma growth characteristics using an animal model that closely
parallels human melanoma. Previously, other studies that attempted to address the issue
of antidepressants and melanoma in vivo utilized melanoma models that do not replicate
tumor biology, such as subcutaneous injection of melanoma cells grown in culture.
Despite the small sample size, this project demonstrates the feasibility of administering
antidepressants to melanoma-bearing mice via the drinking water and conducting weekly
assessments of tumor volume.
In this experiment, oral citalopram at a dose of 20 mg/kg/day did not appear to
affect the growth rate of melanoma tumors. Looking at Figure 3, there appear to be three
distinct patterns of tumor growth: tumors in animals C1 and E4 showed exponential
growth; C2, E1, and E3 showed linear growth over the time course of the experiment;
and E2 had a relatively small tumor burden when the study endpoint was reached.
Grossly, these patterns do not appear to correlate with antidepressant exposure. With
marked variability in the patterns of growth between the two control animals that were
tested, a larger sample size would be needed in order to draw firm conclusions about the
effect of citalopram on tumor growth.
Citalopram was chosen for these experiments because it is a highly serotonergic
antidepressant. However, other antidepressants may influence the growth characteristics
of melanoma in different ways, or by different mechanisms. Thus, future studies could
involve testing other SSRIs or different classes of antidepressants in the Braf/Pten mice.
The 20 mg/kg/day dose of citalopram was in line with other rodent studies of
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antidepressants in the psychiatry literature, but those studies were primarily interested in
the CNS effects of antidepressants. Citalopram (and other antidepressants, as well) are
metabolized differently by mice than by humans, and the action of antidepressants in the
skin may vary across species as well; thus, different drug doses may be needed to achieve
a bioequivalent effect in humans and in mice.
Furthermore, the patterns of antidepressant exposure in this experiment differ
markedly from the ways in which such medications are typically used in humans. Often,
patients with psychiatric diagnoses or chronic pain are maintained on antidepressant
medication for many years prior to presenting with melanoma. The short exposure
duration for the animals in this experiment may have been insufficient to generate an
effect on tumor growth. Additionally, antidepressant exposure in the mice began
simultaneously with tumor induction, whereas antidepressant use in humans frequently
precedes melanoma tumorigenesis. In future studies, animals could be treated with
antidepressants from birth, rather than beginning at the time of tumor induction.
Importantly, the study presented here did not assess tumor latency in control
versus experimental animals, and this may in fact be an important parameter of interest.
Tumor incidence and tumor growth rate may be quite different issues. Because the
Braf/Pten mice develop melanoma with 100% penetrance, an effect of antidepressants on
tumor incidence would be obscured. Tumor latency in the Braf/Pten mouse model might
be a useful surrogate marker for tumor incidence in humans, as prolonging tumor latency
in humans would give the immune system a better chance to mount a response against
malignant cells.
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Though the study was principally designed to investigate the effect of

antidepressants on growth of the primary tumor, organs were visually assessed
macroscopically for metastases. Histologic assessment could be employed in the future to
more accurately determine the presence and/or size of metastatic deposits. With only
two-to-three animals per experimental group involved in this experiment and the
potential for a large number of possible combinations of visceral metastases, the results
presented here must be viewed as inconclusive.
In the event that future studies demonstrate an effect of antidepressants on tumor
growth characteristics, future work could be directed at clarifying the molecular pathways
responsible for the association between antidepressants and melanoma. Two additional
mouse models of melanoma are available at Yale, each with distinct genetic lesions
resulting in tumors that show different clinical behavior. Investigating the differential
effects of antidepressants on animals with different genetic backgrounds could shed light
on the pathways through which antidepressants operate in malignant melanoma.
The results of the case-control analysis failed to support the hypothesis that
melanoma patients would have a higher rate of antidepressant exposure than controls.
Indeed, controls were 1.76 times more likely than melanoma patients to have taken
antidepressant medication. This result is in line with some of the pre-clinical data and at
odds with others. (7, 18, 48-53) While the study presented here represents a good first
step toward characterizing the possible association between antidepressants and
melanoma risk, the following methodological considerations may have impacted the
study outcome.
One of the most important methodological challenges in designing a case-control
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study such as the one presented here is deciding on an appropriate control group. Ideally,
control subjects would be matched to melanoma patients according to race, age, and sex,
at a minimum. Because the control group was younger and more female than the
melanoma cases, age and sex were entered into the binary logistic regression model to
correct for the differences statistically. However, this technique can obscure the effect of
an exposure when it is strongly correlated with other variables in the model. Here,
antidepressant use strongly correlated with female sex, so the analysis was repeated for
males and females separately. No qualitative differences were observed in the repeat
analysis.
Unfortunately, the patient’s race was often not explicitly specified in the
melanoma patients’ charts, so the racial makeup of the melanoma cohort was not reported
in this manuscript. However, melanoma is known to be largely a disease of whites,
affecting only a miniscule number of non-white individuals. In order to maximize the
number of controls available for the analysis, Hispanic subjects were included in the
control group. The cases included a small proportion of subjects whose ethnicity was
documented as Hispanic, but the proportion of Hispanic controls likely exceeded the
proportion of Hispanic cases.
One risk factor that is of the utmost importance in melanoma is sun exposure. Sun
exposure is incredibly difficult to quantify, particularly since the relevant exposure may
occur rather remotely, such as in childhood. Studies attempting to quantify lifetime sun
exposure have used a variety of methods, most relying on detailed surveys or
questionnaires asking subjects to report the geographical locations in which they lived at
various stages of life, as well as details of their occupation and leisure-time activities.
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(56-59) Though a small subset of charts in this study contained information on the
number of sunburns the patient had experienced, this information was insufficient to
characterize overall sun exposure history. Thus, no attempt was made to match cases and
controls for a history of sun exposure in this study.
In an effort to minimize the impact of physician practice patterns on the rate of
antidepressant exposure in the two groups, a hospital-based control group was selected.
Previous case-control studies investigating melanoma risk factors have used populationbased controls recruited by means of random-digit dialing, population registries, and the
like. (56, 57) Hospital-based controls were thought to be more reflective of the
population presenting to Yale Cancer Center for treatment of melanoma.
Notably, the rates of antidepressant use in the control population presented here
far exceeded the rates reported in the literature for the population as a whole, nationwide.
(6) One thing that remains unanswered is whether this difference in rates of
antidepressant use reflects a difference in prescribing habits of primary care physicians
and psychiatrists in Connecticut as compared to the United States overall, or whether
there was in fact something unrepresentative about patients presenting to the plastic
surgery and orthopedic surgery outpatient clinic at Yale and/or those who elected to
participate in the study. The subjects recruited from plastic surgery clinic included
patients being seen in consultation or follow-up for both reconstructive and cosmetic
surgical procedures. Cosmetic surgery patients may be more likely to carry psychiatric
diagnoses and thus more likely to have been treated with antidepressants than the general
population. (60-62) Similarly, reconstructive surgery practices often serve a population of
medically complex, sicker patients, in comparison with the healthier, more active patients
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who sustain orthopedic injuries or develop melanoma after years of sun exposure. Sicker
patients may have higher rates of depression, or they may simply have a greater number
or frequency of contacts with the healthcare system and thus a higher likelihood of being
started on antidepressant medication.
Another methodological weakness of the study presented here is that
antidepressant exposure was ascertained in different ways for cases and controls; for
melanoma patients, information was collected via chart review, whereas control subjects
were queried directly about their medical history and drug exposures. On one hand,
people may be more willing to reveal sensitive information, such as a history of
antidepressant use, to their doctors than to a member of the research staff with whom they
have no preexisting relationship. Questionnaires were completed anonymously, but
subjects may still have had reservations about volunteering information of a personal
nature that seemed irrelevant to their care. On the other hand, the questionnaires
completed by control subjects explicitly asked about antidepressant use, whereas the
physician may have only asked about medications in more general terms. The methods
utilized in this study were chosen for their feasibility in the setting of limited resources,
but the method of data acquisition would have ideally been the same for cases and
controls.
The data presented here failed to demonstrate an association between
antidepressant use and melanoma stage at the time of diagnosis. This pattern held true
whether patients were grouped into three or five categories of stages, as well as when
they were divided into groups based on the presence of in situ or invasive disease.
Neither males nor females showed an effect of tumor stage on likelihood of
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antidepressant exposure. Based on the results of the case-control analysis, any interaction
between antidepressant exposure and melanoma pathogenesis is presumed to be weak
and confounded by a multitude of variables. Thus, this study may not have been
adequately powered to detect an association when dividing the melanoma cohort into
multiple groups.
With limited knowledge of the precise mechanism by which antidepressants
interact with melanoma risk, the relevant details of antidepressant exposure are uncertain.
Other studies in the cancer literature have found effects of antidepressants that were
dependent on dose and duration of treatment, as well as the timing of exposure (i.e.
temporal proximity to cancer diagnosis). Unfortunately, these details were often not
available in the medical record, so for the present study, patients were categorized as
“antidepressant exposed” if they had a record of current or past antidepressant treatment
documented in the chart at the time of melanoma diagnosis. Likewise, the indication for
treatment with an antidepressant would be important to consider when making
recommendations about how to manage melanoma patients on antidepressants, should
further study reveal a deleterious effect on prognosis, but this information was only
infrequently recorded in the chart.
While it would be desirable to characterize the specific details of subjects’
antidepressant use, it may not be practical to contact subjects individually when dealing
with a large cohort of patients, and in some cases, it would not be possible due to death of
a patient or incorrect contact information. Implementation of the electronic medical
record for both inpatient and outpatient visits may yield a powerful tool for more
accurately assessing a subject’s past or present use of antidepressants or other
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medications. Having a centralized medication list that is accessed by all providers may
improve the chances that the charts of sick and non-sick patients alike will contain a
complete medication list, and linking the chart with pharmacy records would provide a
metric for determining whether patients are actually taking the medications that are
prescribed to them.
An important consideration when it comes to evaluating the hypothesis that
antidepressants might increase melanoma risk is whether there might be an underlying
association between cancer risk and depression itself. Here, the data are conflicting.
Depression is characterized by a proinflammatory state reflected by elevated plasma
levels of circulating cytokines that could contribute to neoplastic growth. (63)
Furthermore, a 1998 study of 4825 people over 71 years of age concluded that depression
of at least six years’ duration was associated with increased cancer mortality. (64)
However, a majority of prospective studies point to a weak relationship or none at all
between depression and overall cancer risk. (63, 65-70) Other studies claimed an
increased cancer risk in depressed patients but failed to account for major confounders,
including smoking. (71)
The relationship between depression and melanoma is poorly understood and
undoubtedly complex. Sun exposure increases plasma levels of serotonin, and patients
with mild depression may self-medicate by spending a greater amount of time in the sun.
(10) Conversely, severely depressed patients may lack the energy or motivation to leave
their homes and therefore have decreased sun exposure. For patients with a long history
of depression, the effect of mood on sun exposure could perhaps be enough to impact
overall melanoma risk. Interestingly, one group has shown that 46% of patients with
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melanoma had a major life crisis in the five years preceding melanoma diagnosis,
suggesting that stress may play a role. (72) However, the authors point out that these data
must be interpreted with caution, as people may be more likely to consult a health
practitioner following a stressful event, leading to an increase in melanoma diagnoses.
In the setting of unlimited resources, one way to address the issue of depression as
a confounding factor in the interaction between antidepressants and melanoma would be
to eliminate depression as a variable. This could be done by studying exclusively
depressed subjects with and without a history of treatment with antidepressant
medication, or by excluding patients with depression so that the antidepressant-exposed
population would have been prescribed antidepressants for only non-psychiatric reasons.
To achieve a sufficient number of subjects, such an effort would likely need to be multiinstitutional.
Though the data presented here failed to uncover evidence in support of a causal
link between citalopram and melanoma tumorigenesis, these results must be considered
preliminary in nature. Further study is warranted, given the limitations of the project
presented here. Chart review is ongoing, and we hope to include all patients at Yale
treated surgically for melanoma in future studies on the effect of antidepressants on
melanoma incidence and disease course.
A related question to investigate in the future is whether the proportion melanoma
patients with BRAF-mutant tumors differs between those with and without a history of
antidepressant exposure. BRAF is the most common genetic mutation found in
melanoma, and BRAF mutations are also found at high frequency in benign nevi. Insofar
as antidepressants may facilitate malignant transformation, the effect likely occurs only
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atop a background of genetic mutations. Thus, one would expect to see a higher
proportion of tumors from patients with antidepressant exposure carrying BRAF
mutations, suggesting that they arose from a preexisting nevus.
In the event that further study demonstrates an effect of antidepressants on
melanoma incidence, tumor growth kinetics and/or disease prognosis, the results could
have ramifications for treatment of depression and the other conditions for which
antidepressants are prescribed, particularly in patients diagnosed with melanoma. The
possible implications of this line of research are made even more significant by the sheer
number of patients using antidepressant medication. Evaluation of the hypothesis
outlined in this paper potentially stands to inform the care of the many thousands of
patients each year treated for depression, anxiety, chronic pain or various other medical
conditions.
If, on the other hand, antidepressants prove to have an inhibitory effect on
melanoma incidence, growth, and metastasis, perhaps the beneficial effects of these
compounds could be harnessed and utilized in the treatment of melanoma or in the
prevention of disease in high-risk groups.
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APPENDIX I

Table 1: Classes of antidepressant medication
Selective serotonin reuptake inhibitors (SSRIs)
citalopram (Celexa)
escitalopram (Lexapro)
fluoxetine (Prozac)
paroxetine (Paxil)
sertraline (Zoloft)
Serotonin-norepinephrine reuptake inhibitors (SNRIs)
desvenlafaxine (Khedezla, Pristiq)
duloxetine (Cymbalta)
milnacipran (Savella)
venlafaxine (Effexor)
Atypical antidepressants
agomelatineA
bupropion (Wellbutrin, Zyban)
mirtazapine (Remeron)
Tricyclics
amitriptyline (Tryptomer, Elavil, Endep)
clomipramine (Anafranil)
desipramine (Norpramin, Pertofrane)
doxepin (Adaptin, Sinequan)
imipramine (Tofranil, Janimine, Praminil)
nortriptyline (Pamelor, Aventyl, Norpress)
Monoamine oxidase inhibitors (MAOIs)
phenelzine (Nardil)
selegiline (Eldepryl, Emsam, Zelapar)
tranylcypromine (Parnate)
A

not available in the United States
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APPENDIX II

Table 11. Health History Questionnaire for Control Subjects
1.

Sex:
○ Male
○ Female

2.

Age:

3.

Place of residence (City/Town, State):

4.

Reason for coming into clinic:

5.

Height (feet, inches):

6.

Weight (lbs):

7.

Occupation:

8.

Race/ethnicity (select all that apply):
○ White
○ Black
○ Hispanic

○ Asian
○ American Indian or Alaskan Native
○ Native Hawaiian or Pacific Islander

9.

Skin tone:
○ Pale white
○ Fair
○ Medium
○ Olive
○ Brown
○ Very dark brown

10.

Hair color:

11.

Eye color:

12.

How does your skin react to the first summer sun exposure of the year?
○ Always burns, never tans
○ Usually burns, tans with difficulty
○ Sometimes burns, usually tans
○ Rarely burns, tans easily
○ Very rarely burns, tans very easily
○ Never burns

13.

How many blistering sunburns have you experienced?

14.

How many non-blistering sunburns have you experienced?

15.

Do you sunbathe or use tanning oil or tanning beds?
○ Yes, currently
○ Yes, in my youth
○ Both
○ Neither

16.

Smoking history:
○ I currently smoke
○ I used to smoke but do not currently

	
  

50
○ I have never smoked

17.

If yes to 16: How many packs per day (on average)?

18.

If yes to 16: For how many years?

19.

How many alcoholic beverages do you drink in a typical week?

20.

Have you ever been told you have any of the following medical conditions?
○ High blood pressure
○ High cholesterol
○ Diabetes
○ Heart disease
○ Hyperthyroidism (overactive thyroid)
○ Hypothyroidism (underactive thyroid)
○ Atrial fibrillation
○ DVT (blood clot in leg or arm)
○ Stroke
○ Pulmonary embolism

○ Depression
○ Anxiety
○ Asthma
○ COPD
○ Autoimmune disease (rheumatoid
arthritis, lupus, scleroderma, etc.)
○ Eczema
○ Psoriasis
○ Kidney disease
○ Liver disease

21.

Please list any medical conditions you have that are not listed above.

22.

Please list the type of surgery and the year of surgery for any surgical procedures you have had, or
write “none” if you have never had surgery.

23.

Do you take any of the following anti-inflammatory medications?

24.

Have you ever taken steroid medications by mouth (e.g. prednisone) or other medications that
suppress your immune system? (Do not include topical or inhaled medications, such as creams,
ointments, or inhalers.)
○ No
○ Yes, short-term (less than 2 weeks)
○ Yes, long-term (greater than 2 weeks)

25.

Have you ever taken blood thinners (e.g. warfarin, Coumadin, Lovenox)?
○ Currently taking
○ Have taken in the past
○ Have never taken

26.

Please give the name of medication, dose, start date, and stop date (if applicable) for blood thinners
you have taken, or write “N/A” if you have never taken blood thinners or “unsure” if you do not
know the requested information.

27.

Have you taken any of the following medications which are sometimes used to treat depression,
anxiety, chronic pain, or migraine headaches?
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28.

Please give the dose, start date, and stop date (if applicable) for any of the antidepressant medications
listed above, along with the name of any antidepressants you have taken that are not listed. Write
“N/A” if you have never taken antidepressant medication or “unsure” if you do not know the
requested information.

29.

Have you ever been prescribed thyroid medication (e.g. Synthroid, Levoxyl, levothyroxine, Cytomel,
Thyrolar, Armour thyroid)?
○ Yes
○ No

30.

Please list any other medications you currently take, along with the dose and frequency (if known).
Include vitamins or herbal supplements you take, as well.

31.

Have you ever had a suspicious mole removed?
○ Yes
○ No

32.

Have you ever been diagnosed with melanoma?
○ Yes
○ No

33.

Have you ever been diagnosed with a non-melanoma skin cancer (e.g. basal cell carcinoma,
squamous cell carcinoma)?
○ Yes
○ No

34.

Have you ever been diagnosed with another type of cancer?
○ Yes
○ No

35.

If yes to 34: Please indicate the type of cancer and your age at diagnosis.
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36.

Has anyone in your family been diagnosed with melanoma?
○ Yes
○ No

37.

If yes to 36: Please indicate which of your relatives was diagnosed with melanoma.

38.

Has anyone in your family been diagnosed with another type of cancer besides melanoma?
○ Yes
○ No

39.

If yes to 38: Please indicate the type of cancer and which of your relatives was affected.

	
  

	
  

